You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 162 No. 17, September 23, 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Review Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (37)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Alzheimer Disease
 •Women's Health
 •Menopause
 •Review
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Role of Hormone Replacement Therapy in the Prevention of Alzheimer Disease

Howard M. Fillit, MD

Arch Intern Med. 2002;162:1934-1942.

Alzheimer disease (AD) is the most common form of dementia among the elderly. A higher prevalence of AD in women than in men suggests a link between gonadal hormone levels and AD. Increasing evidence supports a role for estrogen in brain regions involved in learning and memory and in the protection and regulation of cholinergic neurons, which degenerate in AD. Despite the lack of consensus, many studies indicate that hormone replacement therapy may decrease the risk for or delay the onset of AD in postmenopausal women. Recent trials have suggested that estrogen treatment may have no significant effect on the clinical course of AD in elderly women with the disease. Thus, the role of estrogen therapy seems to be confined to primary rather than secondary prevention of AD. Ongoing clinical studies may help to determine the role of estrogen in the cognitive function of postmenopausal women and in the prevention of AD.


From The Institute for the Study of Aging, Inc, New York, NY.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neuroprotective effects of the Alzheimer's disease-related gene seladin-1
Peri and Serio
J Mol Endocrinol 2008;41:251-261.
ABSTRACT | FULL TEXT  

Estrogen and Selective Estrogen Receptor Modulators Exert Neuroprotective Effects and Stimulate the Expression of Selective Alzheimer's Disease Indicator-1, a Recently Discovered Antiapoptotic Gene, in Human Neuroblast Long-Term Cell Cultures
Benvenuti et al.
J. Clin. Endocrinol. Metab. 2005;90:1775-1782.
ABSTRACT | FULL TEXT  

Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women
Kang et al.
Neurology 2004;63:101-107.
ABSTRACT | FULL TEXT  

Copper Perturbation in 2 Monozygotic Twins Discordant for Degree of Cognitive Impairment
Squitti et al.
Arch Neurol 2004;61:738-743.
ABSTRACT | FULL TEXT  

Changes in endometrial blood vessels in the endometrium of women with hormone replacement therapy-related irregular bleeding
Hickey et al.
Hum Reprod 2003;18:1100-1106.
ABSTRACT | FULL TEXT  

Management of Alzheimer's Disease
Grossberg and Desai
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2003;58:M331-353.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.